Medication does not reduce risk of recurrent CV events among patients with diabetes
Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type ...
Mar 30, 2014
0
0